

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 1 064 949 A2**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:

**03.01.2001 Bulletin 2001/01**

(51) Int. Cl. 7: **A61K 45/06, A61P 3/10**

(21) Application number: **00305354.3**

(22) Date of filing: **26.06.2000**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**

Designated Extension States:

**AL LT LV MK RO SI**

(30) Priority: **30.06.1999 US 141780 P**

(71) Applicant: **Pfizer Products Inc.  
Groton, Connecticut 06340 (US)**

(72) Inventor:

**Mylari, Banavara Lakshman  
Groton, Connecticut 06340 (US)**

(74) Representative:

**Simpson, Alison Elizabeth Fraser et al  
Urquhart-Dykes & Lord,  
30 Welbeck Street  
London W1G 8ER (GB)**

(54) **Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications**

(57) This invention is directed to methods, pharmaceutical compositions and kits comprising an aldose reductase inhibitor (ARI), a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug and a selective COX-2 inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said selective COX-2 inhibitor or said prodrug. This invention further relates to methods of using those pharmaceutical compositions for the treatment of diabetic complications such as diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, myocardial infarction, cataracts and diabetic cardiomyopathy.

**EP 1 064 949 A2**

## Description

## BACKGROUND OF THE INVENTION

5 [0001] This invention relates to methods, pharmaceutical compositions and kits comprising an aldose reductase inhibitor (ARI), a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug and a selective cyclooxygenase-2 (COX-2) inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said selective COX-2 inhibitor or said prodrug. This invention further relates to methods of using such pharmaceutical compositions for the treatment of diabetic complications such as diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, myocardial infarction, cataracts and diabetic cardiomyopathy.

10 [0002] Aldose reductase inhibitors function by inhibiting the activity of the enzyme aldose reductase, which is primarily responsible for regulating the reduction of aldoses, such as glucose and galactose, to the corresponding polyols, such as sorbitol and galactitol, in humans and other animals. In this way, unwanted accumulations of galactitol in the lens of galactosemic subjects and of sorbitol in the lens, peripheral nervous cord and kidneys of various diabetic subjects are prevented or reduced. Accordingly, aldose reductase inhibitors are of therapeutic value for controlling certain diabetic complications, e.g., diabetic neuropathy, diabetic nephropathy, diabetic cardiomyopathy, myocardial infarction, cataracts and diabetic retinopathy.

15 [0003] Two forms of cyclooxygenase (COX) are known to exist: COX-1 and COX-2, the former being a constitutive form and the latter being an inducible form. COX-1 exists in the stomach, intestines, kidneys and platelets while COX-2 is expressed during inflammation. Both COX enzyme isoforms metabolize arachidonic by a similar mechanism, but each have different substrate specificities. Selective COX-2 inhibitors are advantageous in the treatment of pain and inflammation while avoiding such side effects as gastric and renal toxicity.

## SUMMARY OF THE INVENTION

25 [0004] This invention is directed to pharmaceutical compositions comprising an aldose reductase inhibitor (ARI), a prodrug thereof or a pharmaceutically acceptable salt of said ARI or of said prodrug; a selective COX-2 inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said selective COX-2 inhibitor or of said prodrug; and a pharmaceutically acceptable carrier, vehicle or diluent.

30 [0005] This invention is also directed to methods of treating a diabetic complication in a mammal comprising administering to said mammal a pharmaceutical composition, as set forth hereinabove. In particular, such diabetic complications as, for example, diabetic neuropathy, diabetic nephropathy, diabetic cardiomyopathy, myocardial infarction, cataracts and diabetic retinopathy can be treated by the methods of this invention.

35 [0006] This invention is also directed to methods of treating a diabetic complication in a mammal comprising administering to said mammal an ARI, a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug; and a selective COX-2 inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said selective COX-2 inhibitor or said prodrug.

[0007] This invention is especially directed to methods wherein the ARI, prodrug thereof or pharmaceutically acceptable salt of said ARI or said prodrug, and the selective COX-2 inhibitor, prodrug thereof or pharmaceutically acceptable salt of said selective COX-2 inhibitor, are administered separately.

40 [0008] This invention is also especially directed to methods wherein the ARI, prodrug thereof or pharmaceutically acceptable salt of said ARI or said prodrug, and the selective COX-2 inhibitor, prodrug thereof or pharmaceutically acceptable salt of said selective COX-2 inhibitor or said prodrug are administered together.

[0009] This invention is also directed to kits comprising:

- 45
- a) a first unit dosage form comprising an aldose reductase inhibitor (ARI), a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug and a pharmaceutically acceptable carrier, vehicle or diluent;
  - b) a second unit dosage form comprising a selective COX-2 inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said selective COX-2 inhibitor or said prodrug and a pharmaceutically acceptable carrier, vehicle or diluent; and
  - 50 c) a container.

[0010] In the compositions, methods and kits of this invention, it is preferred that said ARI is fidarestat, epalrestat, minalrestat, SPR-210, zenarastat or zopolrestat, a prodrug thereof or a pharmaceutically acceptable salt of said ARI or of said prodrug. It is especially preferred that said ARI is zopolrestat, a prodrug thereof or a pharmaceutically acceptable salt thereof or of said prodrug.

55

## DETAILED DESCRIPTION OF THE INVENTION

[0011] The methods, compositions and kits of this invention are useful in treating diabetic complications, including, but not limited to, diabetic neuropathy, diabetic nephropathy, diabetic cardiomyopathy, myocardial infarction, cataracts and diabetic retinopathy.

[0012] The term "treating", as used herein, refers to retarding, arresting or reversing the progress of, or alleviating or preventing either the disorder or condition to which the term "treating" applies, or one or more symptoms of such disorder or condition. The term "treatment", as used herein, refers to the act of treating a disorder, symptom or condition, as the term "treating" is defined above.

[0013] Any aldose reductase inhibitor may be used in the pharmaceutical compositions, methods and kits of this invention. The term aldose reductase inhibitor refers to a compound which inhibits the bioconversion of glucose to sorbitol catalyzed by the enzyme aldose reductase. Such inhibition is readily determined by those skilled in the art according to standard assays (J. Malone, *Diabetes*, 29:861-864, 1980. "Red Cell Sorbitol; an Indicator of Diabetic Control"). The following patents and patent applications, each of which is hereby wholly incorporated herein by reference, exemplify aldose reductase inhibitors which can be used in the compositions, methods and kits of this invention, and refer to methods of preparing those aldose reductase inhibitors: United States Patent 4,251,528; United States Patent 4,600,724; United States Patent 4,464,382, United States Patent 4,791,126, United States Patent 4,831,045; United States Patent 4,734,419; 4,883,800; United States Patent 4,883,410; United States Patent 4,883,410; United States Patent 4,771,050; U.S. 5,252,572; United States Patent 5,270,342; U.S. 5,430,060; United States Patent 4,130,714; United States Patent 4,540,704; United States Patent 4,438,272; United States Patent 4,436,745, United States Patent 4,438,272; United States Patent 4,436,745, United States Patent 4,438,272; United States Patent 4,980,357; United States Patent 5,066,659; United States Patent 5,447,946; United States Patent 5,037,831.


[0014] A variety of aldose reductase inhibitors are specifically described and referenced below, however, other aldose reductase inhibitors will be known to those skilled in the art. Also, common chemical USAN names or other designations are in parentheses where applicable, together with reference to appropriate patent literature disclosing the compound.

[0015] Accordingly, examples of aldose reductase inhibitors useful in the compositions and methods of this invention include:

1. 3-(4-bromo-2-fluorobenzyl)-3,4-dihydro-4-oxo-1-phthalazineacetic acid (ponalrestat, US 4,251,528);
2. N-[(5-trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl-N-methylglycine (tolrestat, US 4,600,724);
3. 5-[(Z,E)- $\beta$ -methylcinnamylidene]-4-oxo-2-thioxo-3-thiazolideneacetic acid (epalrestat, US 4,464,382, US 4,791,126, US 4,831,045);
4. 3-(4-bromo-2-fluorobenzyl)-7-chloro-3,4-dihydro-2,4-dioxo-1(2H)-quinazolineacetic acid (zenarestat, US 4,734,419, and 4,883,800);
5. 2R,4R-6,7-dichloro-4-hydroxy-2-methylchroman-4-acetic acid (US 4,883,410);
6. 2R,4R-6,7-dichloro-6-fluoro-4-hydroxy-2-methylchroman-4-acetic acid (US 4,883,410);
7. 3,4-dihydro-2,8-diisopropyl-3-oxo-2H-1,4-benzoxazine-4-acetic acid (US 4,771,050);
8. 3,4-dihydro-3-oxo-4-[(4,5,7-trifluoro-2-benzothiazolyl)methyl]-2H-1,4-benzothiazine-2-acetic acid (SPR-210, U.S. 5,252,572);
9. N-[3,5-dimethyl-4-[(nitromethyl)sulfonyl]phenyl]-2-methylbenzeneacetamide (ZD5522, U.S. 5,270,342 and U.S. 5,430,060);
10. (S)-6-fluorospiro[chroman-4,4'-imidazolidine]-2,5'-dione (sorbitol, US 4,130,714);
11. d-2-methyl-6-fluoro-spiro[chroman-4,4'-imidazolidine]-2',5'-dione (US 4,540,704);
12. 2-fluoro-spiro[9H-fluorene-9,4'-imidazolidine]-2',5'-dione (US 4,438,272);
13. 2,7-di-fluoro-spiro[9H-fluorene-9,4'-imidazolidine]-2',5'-dione (US 4,436,745, US 4,438,272);
14. 2,7-di-fluoro-5-methoxy-spiro[9H-fluorene-9,4'-imidazolidine]-2',5'-dione (US 4,436,745, US 4,438,272);
15. 7-fluoro-spiro[5H-indenol[1,2-b]pyridine-5,3'-pyrrolidine]-2,5'-dione (US 4,436,745, US 4,438,272);
16. d-cis-6'-chloro-2',3'-dihydro-2'-methyl-spiro[imidazolidine-4,4'-4'H-pyrano(2,3-b)pyridine]-2,5'-dione (US 4,980,357);
17. spiro[imidazolidine-4,5'(6H)-quinoline]-2,5'-dione-3'-chloro-7',8'-dihydro-7'-methyl-(5'-cis) (US 5,066,659);
18. (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide (fidarestat, US 5,447,946); and
19. 2-[(4-bromo-2-fluorophenyl)methyl]-6-fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2,3,5'(2H)-tetrone (minalrestat, US 5,037,831).

All of the foregoing patents disclosing ARI compounds are wholly incorporated herein by reference.

Other aldose reductase inhibitors include compounds of formula A,



A

and pharmaceutically acceptable salts thereof, wherein

Z in the compound of formula A is O or S;

R<sup>1</sup> in the compound of formula A is hydroxy or a group capable of being removed *in vivo* to produce a compound of formula A wherein R<sup>1</sup> is OH; and

X and Y in the compound of formula A are the same or different and are selected from hydrogen, trifluoromethyl, fluoro, and chloro.

A preferred subgroup within the above group of aldose reductase inhibitors includes numbered compounds 1, 2, 3, 4, 5, 6, 9, 10, and 17, and the following compounds of formula A:

20. 3,4-dihydro-3-(5-fluorobenzothiazol-2-ylmethyl)-4-oxophthalazin-1-ylacetic acid [R<sup>1</sup>=hydroxy; X=F; Y=H];
21. 3-(5,7-difluorobenzothiazol-2-ylmethyl)-3,4-dihydro-4-oxophthalazin-1-ylacetic acid [R<sup>1</sup>=hydroxy; X=Y=F];
22. 3-(5-chlorobenzothiazol-2-ylmethyl)-3,4-dihydro-4-oxophthalazin-1-ylacetic acid [R<sup>1</sup>=hydroxy; X=Cl; Y=H];
23. 3-(5,7-dichlorobenzothiazol-2-ylmethyl)-3,4-dihydro-4-oxophthalazin-1-ylacetic acid [R<sup>1</sup>=hydroxy; X=Y=Cl];
24. 3,4-dihydro-4-oxo-3-(5-trifluoromethylbenzoxazol-2-ylmethyl)phthalazin-1-ylacetic acid [R<sup>1</sup>=hydroxy; X=CF<sub>3</sub>; Y=H];
25. 3,4-dihydro-3-(5-fluorobenzoxazol-2-ylmethyl)-4-oxophthalazin-1-ylacetic acid [R<sup>1</sup>=hydroxy; X=F; Y=H];
26. 3-(5,7-difluorobenzoxazol-2-ylmethyl)-3,4-dihydro-4-oxophthalazin-1-ylacetic acid [R<sup>1</sup>=hydroxy; X=Y=F];
27. 3-(5-chlorobenzoxazol-2-ylmethyl)-3,4-dihydro-4-oxophthalazin-1-ylacetic acid [R<sup>1</sup>=hydroxy; X=Cl; Y=H];
28. 3-(5,7-dichlorobenzoxazol-2-ylmethyl)-3,4-dihydro-4-oxophthalazin-1-ylacetic acid [R<sup>1</sup>=hydroxy; X=Y=Cl]; and
29. zopolrestat; 1-phthalazineacetic acid, 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]- [R<sup>1</sup>=hydroxy; X=trifluoromethyl; Y=H].

[0016] In compounds 20-23 and 29, Z is S. In compounds 24-28, Z is O.

[0017] Of the above subgroup, compounds 20-29 are more preferred with compound 29 especially preferred.

[0018] Said compounds of formula A are prepared as disclosed in US 4,939,140, which is wholly incorporated herein by reference.

[0019] The aldose reductase inhibitor compounds of this invention are readily available or can be easily synthesized by those skilled in the art using conventional methods of organic synthesis, particularly in view of the pertinent patent specifications.

[0020] Any cyclooxygenase-2 (COX-2) inhibitor can be used in the pharmaceutical compositions, methods and kits of this invention. The following patents and patent applications exemplify selective COX-2 inhibitors which can be used in the compositions, methods and kits of this invention, and refer to methods of preparing those selective COX-2 inhibitors: United States Patent 5,817,700, issued October 6, 1998; World Patent Application WO97/28121, published August 7, 1997; United States Patent 5,767,291, issued June 16, 1998; United States Patent 5,436,265, issued July 25 1995; United States Patent 5,474,995, issued December 12, 1995; United States Patent 5,536,752, issued July 16, 1996; United States Patent 5,550,142, issued August 27, 1996; United States Patent 5,604,260, issued February 18, 1997; United States Patent 5,698,584, issued December 16, 1997; United States Patent 5,710,140, issued January 20, 1998; United States Patent 5,840,746, issued November 24, 1998; Great Britain Patent Application 986430, filed March 25, 1998; World Patent Application WO97/28120, published August 7, 1997; Great Britain Patent Application 9800689, filed January 14, 1998; Great Britain Patent Application 9800688, filed January 14, 1998; World Patent Application WO94/14977, published July 7, 1994; World Patent Application WO98/43966, published October 8, 1998; World Patent Application WO98/03484, published January 29, 1998; World Patent Application WO98/41516, published September 24, 1998; World Patent Application WO98/41511, published September 24, 1998; Great Britain Patent Application

2,319,032, issued May 13, 1998; World Patent Application WO96/37467, published November 28, 1996; World Patent Application WO96/37469, published November 28, 1996; World Patent Application WO96/36623, published November 21, 1996; World Patent Application WO98/00416, published January 8, 1998; World Patent Application WO97/44027, published November 27, 1997; World Patent Application WO97/44028, published November 27, 1997; World Patent Application WO96/23786, published August 8, 1996; World Patent Application WO97/40012, published October 30, 1997; World Patent Application WO96/19469, published June 27, 1996; World Patent Application WO97/36863, published October 9, 1997; World Patent Application WO97/14691, published April 24, 1997; World Patent Application WO97/11701, published April 3, 1997; World Patent Application WO96/13483, published May 9, 1996; World Patent Application WO96/37468, published November 28, 1996; World Patent Application WO96/06840, published March 7, 1996; World Patent Application WO94/26731, published November 24, 1994; World Patent Application WO94/20480, published September 15, 1994; United States Patent 5,006,549, issued April 9, 1991; United States Patent 4,800,211, issued January 24, 1989; United States Patent 4,782,080, issued November 1, 1988; United States Patent 4,720,503, issued January 19, 1988; United States Patent 4,760,086, issued July 26, 1988; United States Patent 5,068,248, issued November 26, 1991; United States Patent 5,859,257, issued January 12, 1999; World Patent Application WO98/47509, published October 29, 1998; World Patent Application WO98/47890, published October 29, 1998; World Patent Application WO98/43648, published October 8, 1998; World Patent Application WO98/25896, published June 18, 1998; World Patent Application WO98/22101, published May 28, 1998; World Patent Application WO98/16227, published April 23, 1998; World Patent Application WO98/06708, published February 19, 1998; World Patent Application WO97/38986, published October 23, 1997; United States Patent 5,663,180, issued September 2, 1997; World Patent Application WO97/29776, published August 21, 1997; World Patent Application WO97/29775, published August 21, 1997; World Patent Application WO97/29774, published August 21, 1997; World Patent Application WO97/27181, published July 31, 1997; World Patent Application WO95/11883, published May 4, 1995; World Patent Application WO97/14679, published April 24, 1997; World Patent Application WO97/11704, published April 3, 1997; World Patent Application WO96/41645, published December 27, 1996; World Patent Application WO96/41626, published December 27, 1996; World Patent Application WO96/41625, published December 27, 1996; World Patent Application WO96/38442, published December 5, 1996; World Patent Application WO96/38418, published December 5, 1996; World Patent Application WO96/36617, published November 21, 1996; World Patent Application WO96/24585, published August 15, 1996; World Patent Application WO96/24584, published August 15, 1996; World Patent Application WO96/16934, published June 6, 1996; World Patent Application WO96/03385, published February 8, 1996; World Patent Application WO96/12703, published May 2, 1996; World Patent Application WO96/09304, published March 28, 1996; World Patent Application WO96/09293, published March 28, 1996; World Patent Application WO96/03392, published February 8, 1996; World Patent Application WO96/03388, published February 8, 1996; World Patent Application WO96/03387, published February 8, 1996; World Patent Application WO96/02515, published February 1, 1996; World Patent Application WO96/02486, published February 1, 1996; United States Patent 5,476,944, issued December 19, 1995; World Patent Application WO95/30652, published November 16, 1995; United States Patent 5,451,604, published September 19, 1995; World Patent Application WO95/21817, published August 17, 1995; World Patent Application WO95/21197, published August 10, 1995; World Patent Application WO95/15315, published June 8, 1995; United States Patent 5,504,215, issued April 2, 1996; United States Patent 5,508,426, issued April 16, 1996; United States Patent 5,516,907, issued May 14, 1996; United States Patent 5,521,207, issued May 28, 1998; United States Patent 5,753,688, issued May 19, 1998; United States Patent 5,760,068, issued June 2, 1998; United States Patent 5,420,343, issued May 30, 1995; World Patent Application WO95/30656, published November 16, 1995; United States Patent 5,393,790, issued February 28, 1995; and World Patent Application WO94/27980, published February 8, 1994. The foregoing patents and patent applications are wholly incorporated herein by reference.

**[0021]** The activity of the selective COX-2 inhibitors of the present invention may be demonstrated by the following assays. COX-1 activity is determined by methods well known to those skilled in the art. The human cell based COX-2 assay is carried out as previously described (Moore *et al.*, *Inflam. Res.*, **45**, 54, 1996). The *in vivo* Carrageenan induced foot edema rat study is carried out as previously described in Winter *et al.*, *Proc. Soc. Exp. Biol. Med.*, **111**, 544, 1962.

**[0022]** COX-2 selectivity can be determined by methods well known to those skilled in the art and particularly by ratio in terms of IC<sub>50</sub> value of COX-1 inhibition to COX-2 inhibition. In general, it can be said that a compound showing a COX-1/COX-2 inhibition ratio of more than 2 has good COX-2 selectivity.

**[0023]** This invention relates both to methods of treating diabetic complications in which the ARI and selective COX-2 inhibitor are administered together, as part of the same pharmaceutical composition, and to methods in which these two active agents are administered separately, as part of an appropriate dosage regimen designed to obtain the benefits of the combination therapy. The appropriate dosage regimen, the amount of each dose administered and the intervals between doses of the active agents will depend upon the ARI and the selective COX-2 inhibitor being used, the type of pharmaceutical formulations being used, the characteristics of the subject being treated and the severity of the complications. Generally, in carrying out the methods of this invention, an effective dosage for the aldose reductase inhibitors of this invention is in the range of about 0.01 mg/kg/day to 100 mg/kg/day in single or divided doses, preferably

0.1 mg/kg/day to 20 mg/kg/day in single or divided doses and the selective COX-2 inhibitor will be administered in single or divided doses. Selective COX-2 inhibitors will generally be administered in amounts ranging from about 0.01 mg/kg/day in single or divided doses, preferably 10 mg to about 300 mg per day for an average subject, depending upon the selective COX-2 inhibitor and the route of administration. However, some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.

[0024] Administration of the pharmaceutical compositions of this invention can be via any method which delivers a composition of this invention preferentially to the desired tissue (e.g., nerve, kidney, retina and/or cardiac tissues). These methods include oral routes, parenteral, intraduodenal routes, etc. Generally, the compositions of the present invention are administered in single (e.g., once daily) or multiple doses or via constant infusion.

[0025] Pharmaceutical compositions comprising an aldose reductase inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said aldose reductase inhibitor or said prodrug and a selective COX-2 inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said selective COX-2 inhibitor or said prodrug are hereinafter referred to, collectively, as "the active compositions of this invention."

[0026] The active compositions of this invention may be administered to a subject in need of treatment by a variety of conventional routes of administration, including orally, topically, parenterally, e.g., intravenously, subcutaneously or intramedullary. Further, the active compositions of this invention may be administered intranasally, as a rectal suppository or using a "flash" formulation, i.e., allowing the medication to dissolve in the mouth without the need to use water.

[0027] The active compositions of this invention may be administered alone or in combination with pharmaceutically acceptable carriers, vehicles or diluents, in either single or multiple doses. Suitable pharmaceutical carriers, vehicles and diluents include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents. The pharmaceutical compositions formed by combining the active compositions of this invention and the pharmaceutically acceptable carriers, vehicles or diluents are then readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus, for purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.

[0028] For parenteral administration, solutions of the active compositions of this invention in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solutions may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.

[0029] Generally, a composition of this invention is administered orally, or parenterally (e.g., intravenous, intramuscular, subcutaneous or intramedullary). Topical administration may also be indicated, for example, where the patient is suffering from gastrointestinal disorders or whenever the medication is best applied to the surface of a tissue or organ as determined by the attending physician.

[0030] For buccal administration the composition (two active agents administered together or separately) may take the form of tablets or lozenges formulated in a conventional manner.

[0031] For intranasal administration or administration by inhalation, the active compounds of the invention (two active agents administered together or separately) are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

[0032] For purposes of transdermal (e.g., topical) administration, dilute sterile, aqueous or partially aqueous solutions (usually in about 0.1% to 5% concentration), otherwise similar to the above parenteral solutions, are prepared.

[0033] Methods of preparing various pharmaceutical compositions with a certain amount of active ingredient are

known, or will be apparent in light of this disclosure, to those skilled in this art. For examples of methods of preparing pharmaceutical compositions, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 19th Edition (1995).

[0034] The active compositions of this invention contain an amount of both an aldose reductase inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said aldose reductase inhibitor and of a selective COX-2 inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said selective COX-2 inhibitor or said prodrug. The amount of each of those ingredients may independently be, for example, 0.0001%-95% of the total amount of the composition, where the total amount of each may not, of course, exceed 100%. In any event, the composition or formulation to be administered will contain a quantity of each of the components of the composition according to the invention in an amount effective to treat the disease/condition of the subject being treated.

[0035] Since the present invention has an aspect that relates to the treatment of the disease/conditions described herein with a combination of active ingredients which may be administered separately, the invention also relates to combining separate pharmaceutical compositions in kit form. The kit comprises two separate pharmaceutical compositions: an aldose reductase inhibitor, a prodrug thereof or a salt of such aldose reductase inhibitor or prodrug; and a selective COX-2 inhibitor, a prodrug thereof or a salt of said selective COX-2 inhibitor or prodrug as described above. The kit comprises a container for containing the separate compositions such as a divided bottle or a divided foil packet. Typically the kit comprises directions for the administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.

[0036] An example of such a kit is a so-called blister pack. Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process recesses are formed in the plastic foil. The recesses have the size and shape of the tablets or capsules to be packed. Next, the tablets or capsules are placed in the recesses and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are sealed in the recesses between the plastic foil and the sheet. Preferably the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.

[0037] It may be desirable to provide a memory aid on the kit, e.g., in the form of numbers next to the tablets or capsules whereby the numbers correspond with the days of the regimen which the tablets or capsules so specified should be ingested. Another example of such a memory aid is a calendar printed on the card, e.g., as follows "First Week, Monday, Tuesday, ...etc.... Second Week, Monday, Tuesday,..." etc. Other variations of memory aids will be readily apparent. A "daily dose" can be a single tablet or capsule or several pills or capsules to be taken on a given day. Also, a daily dose of the aldose reductase inhibitor can consist of one tablet or capsule while a daily dose of the selective COX-2 inhibitor can consist of several tablets or capsules and vice versa. The memory aid should reflect this.

[0038] In another specific embodiment of the invention, a dispenser designed to dispense the daily doses one at a time in the order of their intended use is provided. Preferably, the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen. An example of such a memory-aid is a mechanical counter which indicates the number of daily doses that has been dispensed. Another example of such a memory-aid is a battery-powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.

[0039] The compositions of this invention generally will be administered in a convenient formulation. The following formulation examples are illustrative only and are not intended to limit the scope of the present invention.

[0040] In the formulations which follow, "active ingredient" means a combination of the compounds of this invention.

#### Formulation 1: Gelatin Capsules

[0041] Hard gelatin capsules are prepared using the following:

Ingredient	Quantity (mg/capsule)
Active ingredient	0.25-100
Starch, NF	0-650

(continued)

Ingredient	Quantity (mg/capsule)
Starch flowable powder	0-50
Silicone fluid 350 centistokes	0-15

[0042] A tablet formulation is prepared using the ingredients below:

Formulation 2: Tablets

[0043]

Ingredient	Quantity (mg/tablet)
Active ingredient	0.25-100
Cellulose, microcrystalline	200-650
Silicon dioxide, fumed	10-650
Stearate acid	5-15

[0044] The components are blended and compressed to form tablets.

[0045] Alternatively, tablets each containing 0.25-100 mg of active ingredients are made up as follows:

Formulation 3: Tablets

[0046]

Ingredient	Quantity (mg/tablet)
Active ingredient	0.25-100
Starch	45
Cellulose, microcrystalline	35
Polyvinylpyrrolidone (as 10% solution in water)	4
Sodium carboxymethyl cellulose	4.5
Magnesium stearate	0.5
Talc	1

[0047] The active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50° - 60°C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 60 U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets.

[0048] Suspensions each containing 0.25-100 mg of active ingredient per 5 ml dose are made as follows:



## Formulation 4: Suspensions

[0049]

Ingredient	Quantity (mg/5 ml)
Active ingredient	0.25-100 mg
Sodium carboxymethyl cellulose	50 mg
Syrup	1.25 mg
Benzoic acid solution	0.10 mL
Flavor	q.v.
Color	q.v.
Purified Water to	5 mL

[0050] The active ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form smooth paste. The benzoic acid solution, flavor, and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume. An aerosol solution is prepared containing the following ingredients:

## Formulation 5: Aerosol

[0051]

Ingredient	Quantity (% by weight)
Active ingredient	0.25
Ethanol	25.75
Propellant 22 (chlorodifluoromethane)	74.00

[0052] The active ingredient is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to 30°C, and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remaining propellant. The valve units are then fitted to the container. Suppositories are prepared as follows:

## Formulation 6: Suppositories

[0053]

Ingredient	Quantity (mg/suppository)
Active ingredient	250
Saturated fatty acid glycerides	2,000

[0054] The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimal necessary heat. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.

[0055] An intravenous formulation is prepared as follows:

## Formulation 7: Intravenous Solution

[0056]

Ingredient	Quantity
Active ingredient	25 mg-10,000 mg
Isotonic saline	1,000 mL

[0057] The solution of the above ingredients is intravenously administered to a patient.

## 15 Claims

1. A pharmaceutical composition comprising an aldose reductase inhibitor (ARI), a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug; a selective COX-2 inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said selective COX-2 inhibitor or said prodrug; and a pharmaceutically acceptable carrier, vehicle or diluent.
2. A composition of claim 1 wherein said ARI is fidarestat, epalrestat, minalrestat, SPR-210, zenarastat or zopolrestat, a prodrug thereof or a pharmaceutically acceptable salt of said ARI or of said prodrug.
3. A composition of claim 2 wherein said ARI is zopolrestat, a prodrug thereof or a pharmaceutically acceptable salt of zopolrestat or of said prodrug.
4. A method of treating a diabetic complication in a mammal comprising administering to said mammal a pharmaceutical composition of claim 1.
5. A method of claim 4 wherein said diabetic complication is diabetic neuropathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic retinopathy, cataracts or myocardial infarction.
6. A method of claim 4 wherein said ARI is fidarestat, epalrestat, minalrestat, SPR-210, zenarastat or zopolrestat, a prodrug thereof or a pharmaceutically acceptable salt of said ARI or of said prodrug.
7. A method of claim 6 wherein said ARI is zopolrestat, a prodrug thereof or a pharmaceutically acceptable salt of zopolrestat or of said prodrug.
8. A method of treating a diabetic complication in a mammal comprising administering to said mammal an ARI, a prodrug thereof or a pharmaceutically acceptable salt of said ARI or of said prodrug and a selective COX-2 inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said selective COX-2 inhibitor or of said prodrug.
9. A method of claim 8 wherein said ARI is fidarestat, epalrestat, minalrestat, SPR-210, zenarastat or zopolrestat, a prodrug thereof or a pharmaceutically acceptable salt of said ARI or of said prodrug.
10. A method of claim 9 wherein said ARI is zopolrestat, a prodrug thereof or a pharmaceutically acceptable salt of zopolrestat or of said prodrug.
11. A method of claim 8 wherein the ARI, prodrug thereof or pharmaceutically acceptable salt of said ARI or said prodrug and the selective COX-2 inhibitor, prodrug thereof or pharmaceutically acceptable salt of said selective COX-2 inhibitor are administered separately.
12. A method of claim 8 wherein the ARI, prodrug thereof or pharmaceutically acceptable salt of said ARI or said prodrug and the selective COX-2 inhibitor, prodrug thereof or pharmaceutically acceptable salt of said selective COX-2 inhibitor are administered together.
13. A kit comprising:

- a) a first unit dosage form comprising an aldose reductase inhibitor (ARI), a prodrug thereof or a pharmaceutically acceptable salt said ARI or said prodrug and a pharmaceutically acceptable carrier, vehicle or diluent;
- b) a second unit dosage form comprising a selective COX-2 inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said selective COX-2 inhibitor or said prodrug and a pharmaceutically acceptable carrier, vehicle or diluent; and
- c) a container.

5

10

15

20

25

30

35

40

45

50

55

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 064 949 A3**

(12)

**EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:  
26.02.2003 Bulletin 2003/09

(51) Int Cl.7: **A61P 3/10**, A61K 45/06,  
A61K 31/415, A61K 31/42,  
A61K 31/19

(43) Date of publication A2:  
03.01.2001 Bulletin 2001/01

(21) Application number: **00305354.3**

(22) Date of filing: **26.06.2000**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(72) Inventor: **Mylari, Banavara Lakshman  
Groton, Connecticut 06340 (US)**

(30) Priority: **30.06.1999 US 141780 P**

(74) Representative:  
**Simpson, Alison Elizabeth Fraser et al  
Urquhart-Dykes & Lord,  
30 Welbeck Street  
London W1G 8ER (GB)**

(71) Applicant: **Pfizer Products Inc.  
Groton, Connecticut 06340 (US)**

(54) **Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications**

(57) This invention is directed to methods, pharmaceutical compositions and kits comprising an aldose reductase inhibitor (ARI), a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug and a selective COX-2 inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said selective COX-2 inhibitor or said prodrug. This invention further relates

to methods of using those pharmaceutical compositions for the treatment of diabetic complications such as diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, myocardial infarction, cataracts and diabetic cardiomyopathy.

**EP 1 064 949 A3**



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 00 30 5354 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
E	EP 1 064 965 A (PFIZER PROD INC) 3 January 2001 (2001-01-03) * claims 1,6-9,17 *	1-13	A61P3/10 A61K45/06 A61K31/415 A61K31/42 A61K31/19
E	EP 1 064 964 A (PFIZER PROD INC) 3 January 2001 (2001-01-03) * claims 1,7,8,10-12 *	1-13	
E	EP 1 251 126 A (PHARMACIA CORP) 23 October 2002 (2002-10-23) * page 7; claims 1,17,43,104,107,109 * * page 119 *	1-13	
Y	EP 0 880 964 A (PFIZER) 2 December 1998 (1998-12-02) * claims 1,4 *	1-13	
Y	WO 99 02189 A (CAMERON NORMAN EUGENE ; CAREY FRANK (GB); ZENECA LTD (GB); COTTER M) 21 January 1999 (1999-01-21) * abstract *	1-13	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K
<b>INCOMPLETE SEARCH</b>			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>13 December 2002</b>	Examiner <b>Gonzalez Ramon, N</b>
CATEGORY OF CITED DOCUMENTS		<p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons 8 : member of the same patent family, corresponding document</p>	
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p>			

EPO FORM 1503 03/82 (PJA/COT)

European Patent  
OfficeINCOMPLETE SEARCH  
SHEET C

Application Number

EP 00 30 5354

Although claims 4-12 are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition:

Claim(s) searched incompletely:  
1-13

Reason for the limitation of the search:

Present claims 1-13 relate to an extremely large number of possible compounds/methods defined as "aldose reductase inhibitor", "selective COX-2 inhibitor" (claims 1,8,11-13), "a prodrug" (claims 1-3,6-13). Support within the meaning of Article 84 EPC and disclosure within the meaning of Article 83 EPC is to be found, however, for only a very small proportion of the compounds/methods claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Furthermore claims 1-14 relate to compounds defined by reference to desirable characteristics or properties, namely "aldose reductase inhibitor", "selective COX-2 inhibitor" (claims 1,8,11-13). The claims cover all compounds having these characteristics or properties, whereas the application provides support within the meaning of Article 84 EPC and disclosure within the meaning of Article 83 EPC for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds specifically mentioned by chemical name in claims 2,3,6,7 with due regard to the general idea underlying the present application.

## PARTIAL EUROPEAN SEARCH REPORT

EPO FORM 1503 03.02 (P04C10)

4

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 30 5354

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

13-12-2002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1064965	A	03-01-2001	BR 0002957 A	30-01-2001
			CA 2313063 A1	30-12-2000
			EP 1064965 A2	03-01-2001
			JP 2001031569 A	06-02-2001
EP 1064964	A	03-01-2001	BR 0002953 A	30-01-2001
			CA 2313131 A1	30-12-2000
			EP 1064964 A2	03-01-2001
			JP 2001039872 A	13-02-2001
			US 2002061918 A1	23-05-2002
			US 6413965 B1	02-07-2002
EP 1251126	A	23-10-2002	EP 1251126 A2	23-10-2002
EP 0880964	A	02-12-1998	AU 725621 B2	19-10-2000
			AU 6380198 A	05-11-1998
			CA 2236553 A1	05-11-1998
			EP 0880964 A2	02-12-1998
			HU 9801022 A2	28-03-2000
			JP 3010153 B2	14-02-2000
			JP 10316588 A	02-12-1998
			NZ 330359 A	23-06-2000
			US 5990111 A	23-11-1999
WO 9902189	A	21-01-1999	ZA 9803720 A	04-11-1999
			AT 205402 T	15-09-2001
			AU 746211 B2	18-04-2002
			AU 8229698 A	08-02-1999
			BR 9810570 A	19-09-2000
			CN 1261804 T	02-08-2000
			CZ 20000017 A3	17-05-2000
			DE 69801661 D1	18-10-2001
			DE 69801661 T2	04-07-2002
			DK 991424 T3	03-12-2001
			EP 0991424 A1	12-04-2000
			ES 2163283 T3	16-01-2002
			WO 9902189 A1	21-01-1999
			HU 0002644 A2	28-12-2000
			JP 2002509540 T	26-03-2002
			NO 20000045 A	06-01-2000
			NZ 501165 A	29-06-2001
			PL 337925 A1	11-09-2000
			PT 991424 T	28-02-2002
			SK 122000 A3	12-06-2000
			TR 9903026 T2	21-04-2000
			US 6337327 B1	08-01-2002

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82



**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 30 5354

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

13-12-2002

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9902189 A		ZA 9805993 A	18-01-1999
WO 9841516 A	24-09-1998	AU 6714298 A	12-10-1998
		WO 9841516 A1	24-09-1998
		EP 0970067 A1	12-01-2000
		JP 2001514668 T	11-09-2001
		US 6071954 A	06-06-2000